Screener
G&A at other companies
Other financials
Where this comes from
Reported directly by Maze Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:GeneralAndAdministrativeExpense.
The source filing: Maze Therapeutics’s 10-Q, filed August 11, 2026.
- Filed
- Aug 11, 2026, 4:48 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001193125-26-344903
| Line item | Three Months Ended June 30, 2026 | Three Months Ended June 30, 2025 | Six Months Ended June 30, 2026 | Six Months Ended June 30, 2025 |
|---|---|---|---|---|
| License revenue | — | — | $20,000 | — |
| Operating expenses: | ||||
| Research and development | 34,940 | 28,108 | 69,088 | 55,688 |
| General and administrative | 13,095 | 8,366 | 25,500 | 16,187 |
| Total operating expenses | 48,035 | 36,474 | 94,588 | 71,875 |
| Loss from operations | (48,035) | (36,474) | (74,588) | (71,875) |
| Other income (expense): | ||||
| Interest and other income, net | 4,239 | 2,795 | 7,450 | 5,410 |
Item 1. Financial Statements (Unaudited)
FAQ
- What is Maze Therapeutics's G&A?
- Maze Therapeutics (MAZE) reported G&A of $13.1M in Q2 2026.
- How has Maze Therapeutics's G&A changed year-over-year?
- Maze Therapeutics's G&A increased by 56.5% year-over-year, from $8.37M to $13.1M.
- What does G&A mean?
- Overhead costs not directly tied to production or sales — corporate management, legal, accounting, office rent, insurance, and other administrative functions.
Ask your AI about Maze Therapeutics's g&a.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude